BioSpace News Archive

Antheia and Ginkgo Bioworks today announced a partnership to accelerate the development and production of essential medicines.

Precision BioSciences, Inc. today announced financial results for the second quarter ended June 30, 2021 and provided a business update.

Oncopeptides AB will publish its report for the second quarter 2021 on August 19 . Investors, financial analysts, and media are invited to participate in a webcast with a QnA session on the same day at 12:00 CEST.

Novozymes delivered 9% organic sales growth in the second quarter and 6% organic sales growth in the first half of 2021. The company has narrowed its full-year financial guidance from previously 2-6% and now expects organic sales growth of 4-6% and an EBIT margin of ~26%, from previously 25-26%.

University Medical Center Utrecht in the Netherlands has signed a 10-year renewal contract for digital pathology with international medical imaging IT and cybersecurity company Sectra.

The UK genomic tools developer, RevoluGen Ltd., announces that its divisional method patent has been granted by the UK Intellectual Patent Office.

Aprea Therapeutics, Inc., a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, announced that the U.S. Food and Drug Administration has placed a clinical hold on its clinical trial evaluating eprenetapopt with acalabrutinib or with venetoclax and rituximab in lymphoid malignancies.

Synlogic, Inc., a clinical stage company bringing the transformative potential of synthetic biology to medicine, reported financial results for the second quarter ended June 30, 2021, and provided an update on its clinical and preclinical programs.

Talaris Therapeutics, Inc. reported financial results for the three- and six-month periods ended June 30, 2021, and provided an update on its business.

CASI Pharmaceuticals, Inc. today reported financial results for the second quarter of 2021.